Teriflunomide Concentration in Serum and Cerebrospinal Fluid From Patients With Multiple Sclerosis
What it found
A paper reports the results; we have not read it yet. See Papers below.
What was tested
Treatment tested
- Teriflunomide
Dihydroorotate dehydrogenase inhibitor
What it measured
Main measures
Concentration of teriflunomide in cerebrospinal fluid
one year
Blood or spinal fluid markersDetermination of the concentration of Teriflunomide in serum and cerebrospinal fluid from patients with multiple sclerosis who are treated with teriflunomide 14 mg daily.
Blood or spinal fluid markers
Other measures (1)
• To determine and quantify transportation of teriflunomide over the blood brain barrier
Who could take part
Relapsing MS · 18 to 65
Inclusion Criteria: * patients with multiple sclerosis treated with teriflunomide 14 mg for at least 6 months Exclusion Criteria: * other immunosuppressive or immunomodulating drugs, other CNS diseases
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
Serum and cerebrospinal fluid will be obtained from 20 patients with relapsing-remitting multiple sclerosis treated with teriflunomide tablets 14 mg daily
Papers
Loading reviews and guidelines…
Related trials
History
Started
Oct 2019
Main results due
Mar 2021
Finished
Jun 2021
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error